Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart dosing-interval extension in CRSwNP (real-world, multicenter)
ChiCTR2600128621Phase 4Not yet recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of stapokibart in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Change from baseline in Nasal Polyp Score (NPS) at Week 24. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on ChiCTR2600128621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128621.